Prescription Pattern in Angiotensin Receptor Neprilysin Inhibitor is Associated with Heart Failure Events

Background: Angiotensin receptor neprilysin inhibition (ARNI) is superior to enalapril in reducing the risk of cardiovascular death and heart failure hospitalization (HFH). However, whether prescription pattern is associated with heart failure outcome is unknown. Method: This is a retrospective stud...

Full description

Saved in:
Bibliographic Details
Published in:Acta Cardiologica Sinica 2023-01, Vol.39 (1), p.144-150
Main Authors: Wei-Tsung Wu, Shih-Han Wang, Ya-Lin Wang, Tsung-Hsien Lin, Wen-Ter Lai, Sheng-Hsiung Sheu
Format: Article
Language:Chinese
Subjects:
Angiotensin receptor neprilysin inhibitor
Cardiac pharmacology
Heart failure
MEDLINE
Prescribing habit
SCIE
Scopus
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 150
container_issue 1
container_start_page 144
container_title Acta Cardiologica Sinica
container_volume 39
creator Wei-Tsung Wu
Shih-Han Wang
Ya-Lin Wang
Tsung-Hsien Lin
Wen-Ter Lai
Sheng-Hsiung Sheu
description Background: Angiotensin receptor neprilysin inhibition (ARNI) is superior to enalapril in reducing the risk of cardiovascular death and heart failure hospitalization (HFH). However, whether prescription pattern is associated with heart failure outcome is unknown. Method: This is a retrospective study of 153 patients who received ARNI in a tertiary medical center in Taiwan. We analyzed the impact of dose up-titration and prescription timing including during initial admission, within 3 months after initial HFH discharge, and at outpatient clinics without prior HFH. The primary endpoint was the composite of cardiovascular death and HFH. Results: After a mean follow-up period of 287 ± 197 days, the primary endpoint occurred in 43 (28.1%) subjects. Patients without and with a primary endpoint significantly differed in terms of history of valvular heart disease (VHD, p = 0.006), ventricular tachyarrhythmia (VT, p = 0.043), percutaneous coronary intervention (p = 0.007), coronary artery bypass grafting (p = 0.002),
format article
fullrecord <record><control><sourceid>hyweb</sourceid><recordid>TN_cdi_hyweb_hyread_00645584</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>00645584</sourcerecordid><originalsourceid>FETCH-hyweb_hyread_006455843</originalsourceid><addsrcrecordid>eNqFicEKgkAQQPdQUJR_0GF-QNgttTpKFHYJie6y2pQDsis7U-HfV9C903u8N1JTo42Js02ynKiImWptsnS5TfV6qqgMyE2gXsg7KK0IBgfkIHd38oKOP37GBnvxAU7YB-qGbzu6lmr6RmLImX1DVvAKL5IWCrRB4GCpewSE_ROd8FyNb7ZjjH6cqcVhf9kVcTu8sK7aIaC9VlpnSZpuktWf_QYur0OE</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Prescription Pattern in Angiotensin Receptor Neprilysin Inhibitor is Associated with Heart Failure Events</title><source>Open Access: PubMed Central</source><creator>Wei-Tsung Wu ; Shih-Han Wang ; Ya-Lin Wang ; Tsung-Hsien Lin ; Wen-Ter Lai ; Sheng-Hsiung Sheu</creator><creatorcontrib>Wei-Tsung Wu ; Shih-Han Wang ; Ya-Lin Wang ; Tsung-Hsien Lin ; Wen-Ter Lai ; Sheng-Hsiung Sheu</creatorcontrib><description>Background: Angiotensin receptor neprilysin inhibition (ARNI) is superior to enalapril in reducing the risk of cardiovascular death and heart failure hospitalization (HFH). However, whether prescription pattern is associated with heart failure outcome is unknown. Method: This is a retrospective study of 153 patients who received ARNI in a tertiary medical center in Taiwan. We analyzed the impact of dose up-titration and prescription timing including during initial admission, within 3 months after initial HFH discharge, and at outpatient clinics without prior HFH. The primary endpoint was the composite of cardiovascular death and HFH. Results: After a mean follow-up period of 287 ± 197 days, the primary endpoint occurred in 43 (28.1%) subjects. Patients without and with a primary endpoint significantly differed in terms of history of valvular heart disease (VHD, p = 0.006), ventricular tachyarrhythmia (VT, p = 0.043), percutaneous coronary intervention (p = 0.007), coronary artery bypass grafting (p = 0.002),</description><identifier>ISSN: 1011-6842</identifier><language>chi</language><publisher>台灣: 中華民國心臟學會</publisher><subject>Angiotensin receptor neprilysin inhibitor ; Cardiac pharmacology ; Heart failure ; MEDLINE ; Prescribing habit ; SCIE ; Scopus</subject><ispartof>Acta Cardiologica Sinica, 2023-01, Vol.39 (1), p.144-150</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Wei-Tsung Wu</creatorcontrib><creatorcontrib>Shih-Han Wang</creatorcontrib><creatorcontrib>Ya-Lin Wang</creatorcontrib><creatorcontrib>Tsung-Hsien Lin</creatorcontrib><creatorcontrib>Wen-Ter Lai</creatorcontrib><creatorcontrib>Sheng-Hsiung Sheu</creatorcontrib><title>Prescription Pattern in Angiotensin Receptor Neprilysin Inhibitor is Associated with Heart Failure Events</title><title>Acta Cardiologica Sinica</title><description>Background: Angiotensin receptor neprilysin inhibition (ARNI) is superior to enalapril in reducing the risk of cardiovascular death and heart failure hospitalization (HFH). However, whether prescription pattern is associated with heart failure outcome is unknown. Method: This is a retrospective study of 153 patients who received ARNI in a tertiary medical center in Taiwan. We analyzed the impact of dose up-titration and prescription timing including during initial admission, within 3 months after initial HFH discharge, and at outpatient clinics without prior HFH. The primary endpoint was the composite of cardiovascular death and HFH. Results: After a mean follow-up period of 287 ± 197 days, the primary endpoint occurred in 43 (28.1%) subjects. Patients without and with a primary endpoint significantly differed in terms of history of valvular heart disease (VHD, p = 0.006), ventricular tachyarrhythmia (VT, p = 0.043), percutaneous coronary intervention (p = 0.007), coronary artery bypass grafting (p = 0.002),</description><subject>Angiotensin receptor neprilysin inhibitor</subject><subject>Cardiac pharmacology</subject><subject>Heart failure</subject><subject>MEDLINE</subject><subject>Prescribing habit</subject><subject>SCIE</subject><subject>Scopus</subject><issn>1011-6842</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFicEKgkAQQPdQUJR_0GF-QNgttTpKFHYJie6y2pQDsis7U-HfV9C903u8N1JTo42Js02ynKiImWptsnS5TfV6qqgMyE2gXsg7KK0IBgfkIHd38oKOP37GBnvxAU7YB-qGbzu6lmr6RmLImX1DVvAKL5IWCrRB4GCpewSE_ROd8FyNb7ZjjH6cqcVhf9kVcTu8sK7aIaC9VlpnSZpuktWf_QYur0OE</recordid><startdate>202301</startdate><enddate>202301</enddate><creator>Wei-Tsung Wu</creator><creator>Shih-Han Wang</creator><creator>Ya-Lin Wang</creator><creator>Tsung-Hsien Lin</creator><creator>Wen-Ter Lai</creator><creator>Sheng-Hsiung Sheu</creator><general>中華民國心臟學會</general><scope>9RA</scope></search><sort><creationdate>202301</creationdate><title>Prescription Pattern in Angiotensin Receptor Neprilysin Inhibitor is Associated with Heart Failure Events</title><author>Wei-Tsung Wu ; Shih-Han Wang ; Ya-Lin Wang ; Tsung-Hsien Lin ; Wen-Ter Lai ; Sheng-Hsiung Sheu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-hyweb_hyread_006455843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>chi</language><creationdate>2023</creationdate><topic>Angiotensin receptor neprilysin inhibitor</topic><topic>Cardiac pharmacology</topic><topic>Heart failure</topic><topic>MEDLINE</topic><topic>Prescribing habit</topic><topic>SCIE</topic><topic>Scopus</topic><toplevel>online_resources</toplevel><creatorcontrib>Wei-Tsung Wu</creatorcontrib><creatorcontrib>Shih-Han Wang</creatorcontrib><creatorcontrib>Ya-Lin Wang</creatorcontrib><creatorcontrib>Tsung-Hsien Lin</creatorcontrib><creatorcontrib>Wen-Ter Lai</creatorcontrib><creatorcontrib>Sheng-Hsiung Sheu</creatorcontrib><collection>HyRead台灣全文資料庫</collection><jtitle>Acta Cardiologica Sinica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wei-Tsung Wu</au><au>Shih-Han Wang</au><au>Ya-Lin Wang</au><au>Tsung-Hsien Lin</au><au>Wen-Ter Lai</au><au>Sheng-Hsiung Sheu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prescription Pattern in Angiotensin Receptor Neprilysin Inhibitor is Associated with Heart Failure Events</atitle><jtitle>Acta Cardiologica Sinica</jtitle><date>2023-01</date><risdate>2023</risdate><volume>39</volume><issue>1</issue><spage>144</spage><epage>150</epage><pages>144-150</pages><issn>1011-6842</issn><abstract>Background: Angiotensin receptor neprilysin inhibition (ARNI) is superior to enalapril in reducing the risk of cardiovascular death and heart failure hospitalization (HFH). However, whether prescription pattern is associated with heart failure outcome is unknown. Method: This is a retrospective study of 153 patients who received ARNI in a tertiary medical center in Taiwan. We analyzed the impact of dose up-titration and prescription timing including during initial admission, within 3 months after initial HFH discharge, and at outpatient clinics without prior HFH. The primary endpoint was the composite of cardiovascular death and HFH. Results: After a mean follow-up period of 287 ± 197 days, the primary endpoint occurred in 43 (28.1%) subjects. Patients without and with a primary endpoint significantly differed in terms of history of valvular heart disease (VHD, p = 0.006), ventricular tachyarrhythmia (VT, p = 0.043), percutaneous coronary intervention (p = 0.007), coronary artery bypass grafting (p = 0.002),</abstract><cop>台灣</cop><pub>中華民國心臟學會</pub></addata></record>
fulltext fulltext
identifier ISSN: 1011-6842
ispartof Acta Cardiologica Sinica, 2023-01, Vol.39 (1), p.144-150
issn 1011-6842
language chi
recordid cdi_hyweb_hyread_00645584
source Open Access: PubMed Central
subjects Angiotensin receptor neprilysin inhibitor
Cardiac pharmacology
Heart failure
MEDLINE
Prescribing habit
SCIE
Scopus
title Prescription Pattern in Angiotensin Receptor Neprilysin Inhibitor is Associated with Heart Failure Events
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T00%3A28%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-hyweb&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prescription%20Pattern%20in%20Angiotensin%20Receptor%20Neprilysin%20Inhibitor%20is%20Associated%20with%20Heart%20Failure%20Events&rft.jtitle=Acta%20Cardiologica%20Sinica&rft.au=Wei-Tsung%20Wu&rft.date=2023-01&rft.volume=39&rft.issue=1&rft.spage=144&rft.epage=150&rft.pages=144-150&rft.issn=1011-6842&rft_id=info:doi/&rft_dat=%3Chyweb%3E00645584%3C/hyweb%3E%3Cgrp_id%3Ecdi_FETCH-hyweb_hyread_006455843%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true